Sarepta Therapeutics

YTD

ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

CEO

Douglas S. Ingram

CEODouglas S. Ingram

Employees

835

Employees835

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1980

Founded1980

Employees

835

Employees835

SRPT Key Statistics

Market cap

1.66B

Market cap1.66B

Price-Earnings ratio

-16.34

Price-Earnings ratio-16.34

Dividend yield

—

Dividend yield—

Average volume

3.02M

Average volume3.02M

High today

$16.81

High today$16.81

Low today

$15.50

Low today$15.50

Open price

$16.57

Open price$16.57

Volume

2.74M

Volume2.74M

52 Week high

$43.92

52 Week high$43.92

52 Week low

$10.42

52 Week low$10.42

Stock Snapshot

Sarepta Therapeutics(SRPT) stock is priced at $15.79, giving the company a market capitalization of 1.66B. It carries a P/E multiple of -16.34.

On 2026-06-07, Sarepta Therapeutics(SRPT) stock traded between a low of $15.50 and a high of $16.81. Shares are currently priced at $15.79, which is +1.9% above the low and -6.1% below the high.

Sarepta Therapeutics(SRPT) shares are trading with a volume of 2.74M, against a daily average of 3.02M.

During the past year, Sarepta Therapeutics(SRPT) stock moved between $10.42 at its lowest and $43.92 at its peak.

SRPT News

Simply Wall St 2d

A Look At Sarepta Therapeutics Valuation After New Shelf Registration For Potential Share Offering - simplywall.st

...

TipRanks 3d

Sarepta Shareholders Approve 2026 Equity and ESPP Plans

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

TipRanks 3d

SRPT Expands Into Huntington’s Disease With New First-in-Human Trial

Sarepta Therapeutics Inc. (SRPT) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from a...

Analyst ratings

48%

of 27 ratings

Buy

29.6%

Hold

48.1%

Sell

22.2%

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.